Category - Developments

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx’s and Par Pharmaceutical’s...

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international...

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine...

Shares of Opiant Pharmaceuticals were approved for listing on the Nasdaq Capital Market at the opening tomorrow (August 29) under the symbol, OPNT.  The company’s common stock had traded on the OTCQB Marketplace since...

An article on Fortune magazine’s web site discusses Titan Pharmaceuticals (NASDAQ:TTNP) and its newest implant with a commonly used Parkinson’s disease drug called ropinirole. Last week, the FDA gave Titan the green...

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson’s disease. A Phase 1/2 clinical study in patients will...

Aphria (TSX:APH; OTCQB:APHQF) has invested $11.5-million in Scientus Pharma’s HydRx Farms unit by way of a 2-year secured debenture convertible into common shares of Scientus Pharma at a rate of $2.75 a share...

Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year...

Closely-held Contextual Genomics has teamed up with CORE Diagnostics to introduce its Find-It genomic test in India. The Find-It test evaluates the mutation status of tumor DNA at more than 120 well-characterized...

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000. Together with more than CDN $6.8-million principal...